| Name | Title | Contact Details |
|---|
MediTech Media, Ltd is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rooted in Relationships, Backed by Results. Our Mission is to revolutionize the perception and impact of employee well-being by creating and proving the correlation of employee well-being with bottom line revenue. To help medium and large-sized organizations by deploying and managing tailored programs that are customized for every client and personalized for each participant. To deliver total Return on Well-being for every client, including individual health improvement, heightened employee engagement, increased productivity, cultural improvement, lower healthcare costs, and higher profitability. Our Vision is to revolutionize the way corporate America values employee well-being by correlating improved employee health and employee engagement with decreased human resources costs and improved financial performance. Our Purpose is to impact our clients’ success and the quality of life of each individual we touch. Through Guaranteed Support; Guaranteed Enjoyment; Guaranteed Improvement you’ll see how we can impact your Return on Well-being (ROW) and improve the health and well-being of your workforce. Connect with us to start the change!
A global decentralized health platform that empowers patients with a self-sovereign health identity and aligns patients, providers, and payers to battle the global pandemic of chronic disease
Surface Oncology is a clinical-stage immuno-oncology company focused on using its specialized knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of next-generation therapies to help patients suffering with cancer. Recent advances in understanding how the immune system fights cancer has created a first wave of immunotherapies with profound benefits for some patients. These first-generation therapies, or "checkpoint inhibitors", have been groundbreaking, but only a relatively small subset of patients is deriving long-term benefit. We believe that the lack of a broad and sustained clinical response is because these first-generation therapies only target one component of the immunosuppressive TME and a broader, more multi-faceted therapeutic approach is required. We are a team on a mission to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Our diverse clinical and preclinical pipeline of immune-enhancing antibody candidates target the innate and adaptive arms of the immune system to deliver dramatically different therapies for patients and their families. Surface is leveraging its deep understanding of TME biology to target factors and cells that suppress patients’ anti-tumor immune response. Our broad attack on the TME has the potential to convert patients’ non-responsive ‘cold’ tumors into immune-active ones. We push ourselves to break through across all dimensions of our work. From a discovery perspective, Surface leverages its world-class SAB to identify new targets and takes an aggressive approach towards generating diverse, highly-specific antibodies, which allows our scientists to thoroughly explore the relevant biology. Our antibody discovery approach generates therapeutic-quality antibodies, as well as unique tools to explore the biology of the tumor microenvironment.
French Family-owned URGO Group is an international leading company and world expert in advanced wound care and selfcare. With its two divisions Urgo Medical and Urgo Consumer Healthcare, URGO Group is engaged on day to day basis with patients, healthcare professionals and the general public. The Group develops innovative wound dressings that have proven their medical superiority through clinical studies, to address an increased need worldwide for the care of chronic wounds. It gives access to responsible healthcare solutions in the areas of first aid, nutritional supplements, sexual well-being, cold and allergies. 3 300 collaborators participate in these missions in 22 countries, among which 10 industrial sites serve the needs of our clients.